Bellerophon Therapeutics, a clinical stage biotherapeutics company, has announced that Jonathan Peacock has been appointed chairman and CEO. Peacock assumes the role from Daniel Tasse, chairman and CEO of Ikaria, who was interim chairman and CEO of Bellerophon since the company's spin-out from Ikaria in February. Tasse will continue as a member of the board of Bellerophon.
Peacock was executive vice president and chief financial officer of Amgen from August 2010 until January 2014. Previously, he was chief financial and administrative officer of Novartis Pharmaceuticals. Peacock also was a partner at McKinsey and Co., a strategy consulting firm, and a partner at PricewaterhouseCoopers.
Peacock said, "I believe the company has great potential, first in the development of three innovative first-in-class programs potentially entering phase III development in the next 12 to 18 months and also in the opportunity to build a broader business around this strong platform of assets and capabilities. In addition, the company's focus on developing new treatments to address important unmet medical needs within the cardiopulmonary and cardiac disease space provides a clear mission to help patients."